✦ LIBER ✦

Aromatase inhibitor development for treatment of breast cancer

✍ Scribed by Shigeru Masamura; Herman Adlercreutz; Harold Harvey; Allan Lipton; Laurence M. Demers; Richard J. Santen; Steven J. Santner

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 649 KB
Volume: 33
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf00666067

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical use of aromatase inhibitors in

Clinical use of aromatase inhibitors in the treatment of breast cancers

✍ Andrea Manni 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 388 KB 👁 1 views

Estrogens are the major hormones supporting the growth of human breast cancer. Aromatization of androgen precursors in peripheral tissues, including the breast cancer itself, is the major source of estrogens in postmenopausal women. Therefore, inhibition of the aromatase enzyme offers an effective m

Aromatase and its inhibitors in breast c

Aromatase and its inhibitors in breast cancer treatment — overview and perspective

✍ Angela M. H. Brodie; Richard J. Santen 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 535 KB

Use of aromatase inhibitors in postmenop

Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

✍ Roseman, Barry J.; Buzdar, Aman U.; Singletary, S. Eva 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 2 views

Surgeons have been involved in the management of metastatic breast cancer since the technique of ovarian ablation was introduced in 1896. However, as newer hormonal and chemotherapeutic regimens were developed, drug therapy gradually replaced surgery as the preferred treatment for metastatic breast

Prognostic value of breast cancer aromat

Prognostic value of breast cancer aromatase

✍ Allan Lipton; Richard J. Santen; Steven J. Santner; Harold A. Harvey; Sherry I. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB 👁 2 views

Adjuvant aromatase inhibitor therapy for

Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data

✍ G. Grana 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone‐sensitive early breast cancer. However, the side‐effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized tria

Summary of aromatase inhibitor clinical

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

✍ Aman U. Buzdar; R. Charles Coombes; Paul E. Goss; Eric P. Winer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge